BioCentury
ARTICLE | Company News

Amgen, Takeda deal

August 6, 2012 7:00 AM UTC

Amgen and Takeda restructured a 2008 deal under which the parties and Takeda's Millennium Pharmaceuticals Inc. subsidiary were co-developing worldwide and sharing profits for Amgen's motesanib. Under the restructured deal, Takeda now has exclusive, worldwide rights to develop and commercialize motesanib. Takeda now has exclusive rights to profits within Japan, and Amgen and Takeda will share profits outside of Japan. Amgen will receive an upfront payment and is eligible for milestones and royalties. Details were not disclosed (see BioCentury, Feb. 11, 2008).

Amgen said in its 2Q12 earnings that the restructured deal was part of its efforts to focus its R&D activities. Last October, Amgen told its R&D staff that it was evaluating changes within the R&D organization (see BioCentury, Oct. 17, 2011 & Oct. 24, 2011). ...